Ru3: a novel ruthenium-based compound overcomes cisplatin resistance in non-small cell lung cancer via the E2F2-IGFBP3-GPX4 pathway
Yiting Lu, Shiming Wu, Ying Jiang, Meishu Wang, Xinyu Liao, Jian Zhang, Junqi Xiang, Hua Yang, Min Yu, Jiang Min, Chen Fu, Yunlong Lei · 2026
Read Ru3: a novel ruthenium-based compound overcomes cisplatin resistance in non-small cell lung cancer via the E2F2-IGFBP3-GPX4 pathway by Yiting Lu, Shiming Wu, Ying Jiang, Meishu Wang, Xinyu Liao, Jian Zhang, Junqi Xiang, Hua Yang, Min Yu, Jiang Min, Chen Fu, Yunlong Lei (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13633971.txt.
Description
Yiting Lu and co-authors present a ruthenium compound called Ru3 for lung cancer that resists cisplatin in a 2026 paper. Resistance to that standard drug is a major hurdle in non small cell lung cancer. The new compound was designed to kill resistant cells while sparing the original sensitive ones.
Ru3 damages mitochondria and raises reactive oxygen in the cells. It boosts a transcription factor that represses a protective protein, weakening an antioxidant defense built on another protein. Resistant cells carry high levels of those protective proteins, which makes them especially vulnerable. The authors name the pathway as a new therapeutic target.
Catalog record
| CREATOR | Yiting Lu, Shiming Wu, Ying Jiang, Meishu Wang, Xinyu Liao, Jian Zhang, Junqi Xiang, Hua Yang, Min Yu, Jiang Min, Chen Fu, Yunlong Lei |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |